Erasca is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Co.'s primary product candidates are ERAS-007 (its oral ERK1/2 inhibitor) and ERAS-601 (its oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. The extracellular signal-regulated kinases (ERK), ERK1 and ERK2, belong to a family of serine-threonine kinases that regulate cellular signaling, and comprise the terminal node of the RAS/MAPK pathway-driven cancers. Co. is pursuing a clinical development plan across multiple tumor types for ERAS-007. We show 11 historical shares outstanding datapoints in our ERAS shares outstanding history coverage, used to compute ERAS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ERAS market cap history over the course of time is important for investors
interested in comparing ERAS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ERAS versus a peer is one thing; comparing
ERAS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ERAS can fluctuate over the course of history.
With this page we aim to empower investors researching ERAS by allowing them to research the ERAS market cap history. |
Free ERAS Email Alerts:
Video: The Importance of Market Cap
